Introduction
============

Connexins (Cxs) are a family of transmembrane (TM) proteins formed by 21 members ([@B27]; [@B111]) named according to their predicted molecular weight (i.e., Cx43 has ∼43 kDa). Cxs are expressed in almost every cell type in the human body ([@B14]). However, there are some differences. Thus, for example, there are Cxs widely expressed such as Cx43, which is found in the brain, kidneys, heart and reproductive organs, among others ([@B10], [@B9]; [@B97]), or restricted to myelin-forming glial cells, as in the case of Cx29 ([@B110]). Cxs form two types of channels; hemichannels (HCs) and gap junction channels (GJCs). HCs are formed by the oligomerization of six Cxs monomers and travel in vesicles to the plasma membrane ([@B122]). The Cx topology in cell membrane is depicted in **Figure [1](#F1){ref-type="fig"}** and includes four TM segments (TM1-4), which are connected through two extracellular loops (EL1-EL2) and one intracellular loop (IL); and the N-terminal (NT) and C-terminal (CT) segments oriented to the cytosol ([@B55]). HCs can form GJC in the appositional membranes of contacting cells or stay as "free" HCs anywhere on the plasma membrane (**Figure [2](#F2){ref-type="fig"}**). Free HCs are mostly closed under physiological conditions ([@B21]), that is because they have low open probability (OP) due to one or more of the following mechanisms: (i) a blockage by extracellular Ca^2+^ and Mg^2+^ in the mM range, (ii) a negative membrane potential that closes most Cx HCs and (iii) posttranslational modification (i.e., phosphorylation) of some Cxs ([@B21]; [@B38]; [@B51]). However, HCs can open under physiological conditions allowing communication between extracellular and intracellular space ([@B99]). On the other hand, GJCs are formed in the appositional membrane by the serial docking of two complementary HCs, each one in the respective neighboring cell membrane (**Figure [2](#F2){ref-type="fig"}**). GJCs allow the intercellular exchange of ions and molecules such as glucose and amino acids between contacting cells ([@B84]; [@B37]; [@B28]). Because of these properties, Cx based channels have been associated with different cellular processes such as cellular communication and tissue coordination ([@B99]).

![**Topology of connexin (Cx) at the plasma membrane.** Cartoon depicting the plasma membrane topology shared by all Cx isoforms, which includes four transmembrane (TM) segments that are connected by two extracellular loops (ELs) and one intracellular loop (IL). The amino terminal (NT) and carboxi terminal (CT) segments of each hemichannel face the cytoplasm. The length of the NT and CT segments is not intended to represent any particular Cx isoform.](fncel-09-00267-g001){#F1}

![**Plasma membrane arrangements of Cxs.** Six Cxs oligomerize to form a HC that traveled to the non-appositional plasma membrane to form free HCs, which provide an auto/paracrine communication pathway between the cell and the extracellular milieu. Alternatively, can dock others HCs provided by an adjacent cell (appositional plasma membrane) to form intercellular aqueous pore named gap junction channels.](fncel-09-00267-g002){#F2}

Role of HCs in Physiological Conditions
=======================================

HCs have an estimated pore diameter ranging from 12 to 15 Å in its narrowest part ([@B77]; [@B39]; [@B88]). The crystal structure of Cx26 channels shows that the NT is inside the pore, a factor that restricts the pore diameter ([@B64]). However, recent refinements of this structure using molecular dynamic methods suggest that the pore diameter could be a little smaller ([@B56]). Much experimental evidence shows that opening of HCs activates pathways linked to the release or uptake of paracrine and autocrine molecules such as: ATP ([@B2] (Cx26); [@B116] (Cx30); [@B75] (Cx32); [@B106] (Cx36); [@B114] (Cx43)), glutamate ([@B118] (Cx32); [@B130] (Cx43)), PGE~2~ ([@B18] (Cx43)), NAD^+^ ([@B13] (Cx43)) and glutathione ([@B89] (Cx43)). HCs may also mediate uptake of glucose as well as extracellular ions. ([@B94] (Cx43); [@B105] (Cx43); [@B102] (Cx26); [@B32] (Cx26)). Research about HC permeability has been focused mostly on homomeric HCs made by Cx26, Cx32 and Cx43. However, most cell types express more than one Cx isoform, opening the possibility for the formation of heteromeric channels that would present new permeability properties ([@B8]; [@B67]). For example, it is known that heteromeric HCs formed by Cx26/32 (1:1 ratio) exhibits decreased permeability to (1,4,5)-IP~3~ compared to the respective homomeric types formed by Cx26 or Cx32 ([@B3]). Additionally, information about the *in vivo* release of molecules through HCs is currently very limited. However, data available suggest that HCs are somehow involved in different physiological processes, such as the control of monocyte adhesion in mice ([@B127]), neurotransmitter release from astrocytes in the basolateral amygdala ([@B112]), Ca^2+^ signaling in adult ventricular myocytes ([@B58]), sensory neuron activity ([@B92]), and bone cell physiology and pathology ([@B85]). Moreover, HCs may also participate in the ATP release from astrocytes to regulate basal glutamatergic synaptic transmission ([@B19]), in the control of colonic transit ([@B68]), in wound healing ([@B117]), in renal function ([@B109]), ion flux in lens cells ([@B7]; [@B65]) and in the visual processing of the retina ([@B52]). The signaling and molecular mechanisms that control the opening of HCs under physiological conditions are poorly understood. But, at least for Cx43 HCs, one possible mechanism involves interactions between the CT and some regions of the IL ([@B86], [@B87]).

The presence and functional state of HCs in the plasma membrane have been determined through several techniques, including, dye uptake of fluorescent molecules, release of substances such as ATP, electrophysiology, biotinylation, immunolocalization ([@B104]; [@B124]; [@B34]). Because the existence of other non-selective channels with big pores, like Pannexin channels, which share several characteristics with Cx HCs, there are some criterions that need to be considered in order to demonstrate unique functional properties of Cx HCs ([@B98]). Among these criterions are: (i) cell expression of at least one Cx isoform at the plasma membrane, (ii) the ability of the cells to incorporate/release fluorescent dyes, and /or (iii) to show currents with conductance and/or properties associated to Cx HCs, (iv) the abolishment of Cx-HCs function using classical pharmacology (La^3+^, mefloquine, carbenoxolone) or Cx mimetic peptides (Gap 26, 27); and finally (v) to demonstrate that blocking Cx HCs exerts physiological responses.

Leaky HCs
=========

[@B83] provided the first evidence linking HCs with cell death, they observed that overexpression of Cx46 in *Xenopus laevis* oocytes, induces depolarization and lysis of oocytes 24 h after mRNA injection. Interestingly, cell death did not occur when other Cxs, like Cx32 or Cx43 were overexpressed. Later on, it was demonstrated that human Cx43 does not form functional HCs in *Xenopus* oocytes ([@B45]), suggesting that formation of functional HCs depends on both Cx isoform and cell type. On the other hand, several works have shown that many pathological conditions produce uncontrolled and massive HC opening (from now called leaky HCs), which may adversely affect cellular homeostasis and induce cell death ([@B99]). For example, it was reported that infection of the gastrointestinal tract increases Cx43 HC activity in colonocytes, which was correlated with an increase of water mobilization and appearance of diarrhea, which can be reverted by down-regulating gut expression level of Cx43 ([@B41]). In addition, natural occurring Cx mutations have been associated with different human genetic diseases such as cataract, skin diseases, deafness, X-linked Charcot--Marie--Tooth disease, and oculodentodigital dysplasia (ODDD; **Table [1](#T1){ref-type="table"}**). Some Cx mutations in these diseases produce leaky HCs when expressed in heterologous expression systems. Here, we will review the current knowledge about these leaky HCs and their possible pathologic mechanisms of disease.

###### 

Connexin (Cx) mutations associated to leaky HCs.

                       Cx     Mutation   Localization   Type of disease                                          Reference
  -------------------- ------ ---------- -------------- -------------------------------------------------------- -----------------
  Skin and inner ear   Cx26   G12R       NT             Keratitis-ichthyosis-deafness (KID) syndrome             [@B57]
                              N14K       NT             Keratitis-ichthyosis-deafness syndrome                   [@B57]
                              N14Y       NT             Keratitis-ichthyosis-deafness syndrome                   [@B34]
                              A40V       TM1/EL1        Keratitis-ichthyosis-deafness syndrome                   [@B101]
                              G45E       TM1/EL1        Keratitis-ichthyosis-deafness syndrome                   [@B113], [@B36]
                              D50N       EL1            Keratitis-ichthyosis-deafness syndrome                   [@B57]
                              D50A       EL1            Keratitis-ichthyosis-deafness syndrome                   [@B71]
                              A88V       TM2            Keratitis-ichthyosis-deafness syndrome                   [@B71]
  Skin                 Cx30   G11R       NT             Hidrotic ectodermal dysplasia                            [@B29]
                              A88V       TM2            Hidrotic ectodermal dysplasia                            [@B29]
                       Cx31   R42P       TM1/EL1        Erythrokeratodermia variabilis                           [@B20]
                       CX43   G8V        NT             Keratoderma-hypotrichosis-leukonychia totalis syndrome   [@B123]
  Lens                 Cx46   G2D        NT             Nuclear pulverulent and posterior polar cataracts        [@B129]
                              G143R      IL             Coppock cataracts                                        [@B90]
                       Cx50   V44A       TM1/EL1        Suture-sparing nuclear cataracts                         [@B134]
                              G46V       E1             Cataract                                                 [@B121]
  Nervous system       Cx32   F235C      CT             Charcot--Marie--Tooth disease                            [@B61]
                              S85C       TM2            Charcot--Marie--Tooth disease                            [@B1]
                       Cx43   G60S       EL1            Oculodentodigital dysplasia                              [@B54]
                              G138R      IL             Oculodentodigital dysplasia                              [@B24]
  Heart                Cx40   G38D       TM1            Chronic atrial fibrillation                              [@B82]
                              V85I       TM2            Atrial fibrillation                                      [@B115]
                              L211I      TM4            Atrial fibrillation                                      [@B115]
                       Cx43   I31M       TM1            Spontaneous arrhythmias                                  [@B25]
                              G138R      IL             Spontaneous arrhythmias                                  [@B25]
                              G143S      IL             Spontaneous arrhythmias                                  [@B25]

Leaky HCs can result from single point mutations. Mutations in different Cxs can lead the development of different diseases with hallmark characteristics. Note that most mutations leading to formation of leaky HCs are located in the N- terminus (NT), the extracellular loop 1 (EL1) and transmembrane domains 1 and 2 (TM1 and TM2). In a lesser extent, some mutations are found in the intracellular loop (IL) or the transmembrane domain 3 and 4 (TM3 and TM4). In terms of leaky HCs, mutations in C-terminal are rarer, probably because the first half of the protein including (NT, TM1, EL1, TM2 and IL) is much more important in terms of pore formation, permeability and voltage gating.

Cataract
--------

Lens cells express Cx43, Cx46, and Cx50 ([@B7]). Until now, Cx43 mutations have not been associated with cataract formation; however, the lack or malfunctioning of Cxs 46 and 50 has been associated with the development of different types of cataracts ([@B7]). Accordingly, the expression of Cx50G46V mutant in *Xenopus* oocytes induces large HC currents at physiological extracellular Ca^2+^ concentration ([@B121]). In addition, this mutant promotes cell death when expressed in HeLa cells, which was prevented by the increase of the extracellular Ca^2+^ concentration ([@B72]). Similarly, Cx50V44A mutant also induces HeLa cell death, which was reduced by HC blockers ([@B134]). The aforementioned data suggest that some Cx50 mutations located closely to the TM1 and EL1 border result in formation of leaky HCs, which cause cataracts when expressed in humans. Additionally, different Cx46 mutations have been associated with leaky HCs. For example, mutant Cx46G143R (located in the IL) leads to the appearance of Coppock cataracts ([@B90]), and mutant Cx46G2D (located the NT) has been linked to formation of nuclear pulverulent and posterior polar cataracts ([@B129]). Lower plasma membrane expression of these mutants was enough to promote cell death when expressed in HeLa cells ([@B90]). This suggests that mutation Cx46G143R induces an important increase in the HC activity, possibly by modifying the interaction between the CT and IL, which is associated with HC opening ([@B90]). A possible explanation for the pathological mechanism of leaky Cx46 HCs is that the opening of these channels produces an excessive flow of Ca^2+^ through the plasma membrane ([@B26]; [@B65]), which should perturb the normal ionic balance of lens cells (**Figure [3](#F3){ref-type="fig"}**).

![**Representation of the effects of leaky HC.** Under normal conditions **(upper panel)** HCs present a low open probability (OP). Thus, when HCs are normally closed (*t*~0~, low OP), no exchange with the extracellular milieu is observed. However, when HCs open (*t*~1~, higher OP), molecules such as ATP and Ca^2+^ can flow through them. Calcium may activate intracellular pathways, and ATP released from the cell, can act as a paracrine -or autocrine- signal, hence, the cell is at a communicating state. In contrast leaky HCs **(lower panel)** maintain a high OP, producing a continuous flow out and into the cell. Leaky HCs exchange continuously, resulting in the reduction of cell membrane potential and later cell death (*t*~2~).](fncel-09-00267-g003){#F3}

Skin Diseases and Deafness
--------------------------

Several Cx types such as Cx26, Cx30, Cx30.3, Cx31.1, Cx37, and Cx43 are differentially expressed in the skin ([@B107]). On the other hand, while in the inner ear the sensory hair cells do not express Cxs, several Cxs (Cxs 26, 29, 30, 31, 43) are expressed in supporting epithelial cells of the organ of Corti, stria vascularis and in the interstitial cellular network that compose the wall of the scala media ([@B66]). However, until now, only mutations in Cx26 gene are associated to syndromic (deafness plus skin disease) and non-syndromic deafness ([@B44]; [@B66]). Currently it is known that several missense point mutation in Cx26 -- G12R, N14K, N14Y, A40V, G45E, D50N, D50A and A88V do form leaky HCs and induce both skin and hearing disorders, which together are known as keratitis-ichthyosis-deafness (KID) syndrome ([@B113]; [@B36]; [@B57]; [@B35]; [@B71]; [@B69]; [@B101]). Interestingly, [@B34] showed that the mutant Cx26S17F presents decreased HC activity when expressed alone in *Xenopus* oocytes, but when is co-expressed with Cx43 \[which does not form functional HCs in *Xenopus* oocytes ([@B42])\], a large HC current is then evident ([@B34]). Because of these leaky HCs, HeLa cells expressing Cx26S17F and Cx43 showed almost twice the basal intracellular Ca^2+^ concentration ([@B34]). These results could explain the resulting KID syndrome of the mutant S17F, since in the human skin Cx26 and Cx43 are co-expressed in keratinocytes of the stratum basal ([@B126]). In addition, certain mutations located in the EL1 also produce leaky HCs, such as D50N, that change the Ca^2+^ control over HC activity through the modification of a salt bridge between D50 and K61, which is important for HC closure induced by extracellular Ca^2+^ ([@B62]; [@B103]). Consistently, a similar mutation (Cx26D50A) also induces leaky HC and produce KID syndrome ([@B71]). On the other hand, mutant Cx26A40V, located in the TM1/EL1 border, increases HC activity by decreasing sensitivity to pH and divalent cations ([@B101]). However, other mutation in the same residue (A40G) produced non-functional HCs ([@B48]) and severe deafness without skin disease, suggesting that this residue is positioned in a pivotal region for HC gating control. Another mutant associated with KID syndrome, Cx26G45E ([@B40]) also induces large HC currents or dye uptake that leads to cell death when expressed in *Xenopus* oocytes or HEK293 cells ([@B113]; [@B36]). The phenotype induced by the Cx26G45E mutant could be the result of a lack of Ca^2+^ control ([@B132]), reflected by enhanced Ca^2+^ permeability in cells expressing this mutant ([@B101]). In a mouse model, Cx26G45E induces a reduction of cell viability, hyperkeratosis, scaling, skinfolds, and hair loss ([@B70]). These data suggest that leaky Cx26 HCs can induce skin problems and deafness, probably due to misregulation of intracellular Ca^2+^ homeostasis and ATP release ([@B34]) (**Figure [3](#F3){ref-type="fig"}**); both conditions could affect many cellular processes, such as abnormal keratinocyte proliferation and cell death. Although, most mutations in Cx26 associated with deafness produce lack of function GJCs, only syndromic mutations produce gain of HC activity ([@B66]; [@B35]). However, since syndromic mutations also affect GJCs, the pathogenic mechanism of disease may involve deregulation of both types of channels, which is a condition that would worsen the cellular homeostasis ([@B34]).

Mutations in Cx30 have been also linked to skin disease. Thus, mutants of Cx30- G11R (NT) and A88V (TM2) has been associated with Clouston syndrome (abnormal formation of ectodermal structures) and when they are expressed in HeLa cells induce a massive release of ATP into the extracellular medium ([@B29]) and subsequent cell death ([@B5]), suggesting uncontrolled HC activity. On the other hand, the mutant Cx31R42P (which produces erythrokeratodermia variabilis) promotes an enhancement in HC activity and cell death when expressed in HeLa cells ([@B20]). It was postulated that the previous condition was mediated by an important production of free radicals as consequence of ER stress ([@B20]). Recently, a mutation in Cx43 (Cx43G8V) has been associated to keratoderma-hypotrichosis-leukonychia totalis syndrome (KHLS), a condition characterized by hyperkeratosis and alopecia, the expression of this mutant induced gain in HC activity and Ca^2+^ influx into the cells ([@B123]).

X-linked Charcot--Marie--Tooth Disease
--------------------------------------

This neuropathy is a hereditary disease caused by different mutations in Cx32 gene ([@B6]). There are several Cx32 mutations that induce Charcot--Marie--Tooth disease ([@B61]). Patients with this disease present neurodegeneration due to altered myelin production by Schwann cells ([@B6]). When the mutation Cx32F235C (CT) is expressed in *Xenopus* oocytes, it induces cell death after 72 h, which was associated with changes in its voltage sensitivity ([@B61]). In addition, the other pathological mutant Cx32S85C induces a decrease in the number of HCs at the plasma membrane (measured as biotinylated protein). However, when this mutant was expressed in oocytes, larger HC currents were observed under depolarization ([@B1]). Thus, several mutations induce this disease, but to date only two of them have been reported to form leaky HCs.

Oculodentodigital dysplasia
---------------------------

It is a dominant negative inherited disorder caused by mutations in Cx43 encoding gene. ODDD's patients exhibit abnormalities in fingers, toes, eyes, face and teeth. Mice expressing human mutations Cx43- G138R or G60S, mimic the phenotype observed in humans ([@B24]; [@B54]). In the case of mice +/G60S, the area of cell death induced by brain ischemia was bigger compared to control mice; accordingly, astrocytes cultured from +/G60S mice, show enhanced HC activity ([@B54]). In the other hand, mutant Cx43G138R lacks one of the typical phosphorylated forms of Cx43 (P2), and cells extracted from the +/G138R mice present increased ATP release ([@B24]). The previous results were consistent with the hypothesis that the phosphorylation state of the Cx43 CT regulates Cx43 HC activity.

Heart Disease
-------------

Heart cells express Cx40, Cx43, and Cx45. However, their respective expression is restricted to few types of cells in the heart ([@B4]). For example, Cx40 is expressed only in the atria and ventricular conduction system, while Cx43 is mostly expressed in cardiomyocytes ([@B4]). Several Cx40 mutations have been associated with atrial-fibrillation problems, but only mutants Cx40- G38D, V85I and L211I enhance HC activity ([@B82]; [@B115]). In the case of G38D, it was found that HCs formed by this mutant present a gain of activity when N2A cells were subjected to hyperpolarization and depolarization ([@B82]). Cx43- I31M, G143S and G138R mutants (which also induce ODDD), present spontaneous arrhythmias, which were associated with both, a decrease of GJC coupling and an increase of ATP release from cardiomyocytes ([@B25]). A few years ago, it was demonstrated that down-regulation of Cx43 in cardiac fibroblasts reduce the amount of ATP released ([@B63]). The ATP released activates the pro-fibrotic response to heart insults via activation of P2Y receptors ([@B63]). Thus, increased Cx43 HC activity after -for example- myocardial infarction ([@B50]; [@B49]) will lead to cardiomyocyte malfunction due to a massive entry of Ca^2+^ and Na^+^ ([@B59]). In addition, it will also contribute to cardiac fibrosis ([@B63]) increasing heart failure.

Central Nervous System Neurodegenerative Diseases
=================================================

Under physiological conditions HCs participate in important functions of the nervous system (NS), as for example, in synaptic modulation ([@B112]; [@B19]). Moreover, it has been shown that some pathological conditions increase HC activity, in particular the activity of astrocyte HCs formed by Cx43, which have been correlated with neuronal malfunctioning and death ([@B81]). When an ischemic episode occurs, astrocytes open their Cx43 HCs ([@B22]; [@B93]), probably due to dephosphorylation and *S*-nitrosylation of Cx43 ([@B93]). The previous conditions induce a massive opening of astrocyte Cx43 HCs allowing the release of high amounts of ATP and glutamate from astrocytes ([@B78]; [@B60]). This increment in extracellular ATP and glutamate concentration could induce the opening of neuronal Pannexin1 channels, perturbing neuron homeostasis causing cell death ([@B78]). Consistently, administration of Cx43 mimetic peptides, to block HCs, improved brain recovery after ischemia in fetal sheep ([@B23]) and neonatal rats ([@B60]).

Hyperactive HCs may also be involved in other brain diseases. Lysosomal storage diseases (LSDs) encompass a large group of inherited metabolic disorders characterized by the accumulation of storage material within lysosomes and HCs seems to have a relevant role in the progression of these diseases ([@B12]). In this line, an enhanced Cx43 HC activity was observed in astrocytes from a mouse model of LSD (CLN3^Δex7/8^; [@B31]; [@B15]) which could importantly contribute to neuronal deterioration as mentioned above. On the other hand, opening of HCs could also contribute to brain deterioration in Alzheimer's disease. [@B79] reported that Aβ peptide induces massive HC opening in astrocytes, microglia, and neurons, either in culture and in hippocampal slices ([@B79]). This increase of HC activity is correlated with augmented release of neuroactive molecules, such as glutamate and ATP, with induction of cellular death ([@B79]; [@B12]). Accordingly, blockage of HCs improved memory impairment in a mouse model of Alzheimer's disease ([@B119]). Other neurodegenerative diseases in which HC have been involved are: HIV encephalitis ([@B30]; [@B80]), amyotrophic lateral sclerosis ([@B11]; [@B128]; [@B119]), Parkinson's disease ([@B96]; [@B53]), Rasmussen encephalitis ([@B16]) and epilepsy ([@B73]). A common milestone of these diseases is the inflammation condition, where cytokines and reactive oxygen species (ROS) can activate HCs in glial cells (astrocytes and microglia; [@B94]) increasing the extracellular concentration of compounds, like ATP and glutamate, that could indirectly open Pannexin1 channels leading to neuronal death ([@B81]; [@B12]; [@B120]).

Future Directions
=================

When opened in a controlled fashion, Cx HCs allow physiological paracrine and autocrine communication between neighboring cells. However, under certain pathological conditions, these HCs open more frequently, inducing ionic imbalance and cell lysis. In particular, specific missense mutations in Cx genes associated with human genetic disease produce leaky HCs, a condition that perturbs ionic cell homeostasis, increases ATP release and Ca^2+^ influx, which in the extreme condition leads to cell death. Probably, the major problem in the study of Cx- based channels is the lack of specific pharmacological tools able to block or open these channels. Thus, for example, one of the most used HC blockers is La^3+^ (usually used at 200 μM), but this lanthanide also blocks TRP channels ([@B133]), cGMP-activated currents ([@B125]) and Ca^2+^ channels ([@B74]). Fortunately, in the last years new tools have been developed for the study of Cx- HCs. These are based on small peptides that mimic some regions of a given Cx ([@B47]). Through the use of these mimetic peptides it has been possible to study *in vitro*/*in vivo* the role of HCs in a much more specific way. Because of their specificity and high affinity, they could be used for the treatment of diseases associated with leaky HCs. In this line of thought, mimetic peptides Gap26 or Gap27 have been observed to block cardiomyocyte death induced by ischemic-like conditions *in vitro* ([@B108]) as well as *in vivo* ([@B43]). In the NS, Gap26 and Gap27 peptides blocked Cx43 HC opening induced by inflammatory conditions ([@B94]; [@B33]), while Gap27 reduced spontaneous epileptiform activity in organotypic hippocampal slice cultures and cell death associated with this activity ([@B100]; [@B131]). On the other hand, mimetic peptide Gap26 inhibits the spread of damage from the trauma zone to the penumbra in an *in vitro* model ([@B95]). Similar results have been observed *in vivo* in a model of spinal cord injury ([@B46]; [@B76]) and post-ischemic brain injury ([@B23]). Moreover, inhibition of Cx43 HCs with mimetic peptides in the spinal cord, significantly reduced the sensitization to neuropathic pain ([@B17]), which suggests that opening of HCs could result in an excessive release of neuroactive molecules in chronic pain. Accordingly, exposure of sensory ganglia to mimetic peptides, to block Cx43 HCs of satellite glial cells, reduced sensory neuron activity ([@B91],[@B92]). Therefore, mimetic peptides could be used as the starting point to develop new and more specific pharmacologic agents to inhibit HCs to treat human diseases associated to leaky HCs.
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